ATL 201

Drug Profile

ATL 201

Alternative Names: Astatine-211-J591; Astatine-211-labelled-anti-PSMA monoclonal antibody J591

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator ATLAB Pharma
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 18 Jan 2017 Atlab Pharma and Telix Pharmaceuticals plan a phase IIb trial for in Prostate cancer (Metastatic disease)
  • 18 Jan 2017 Preclinical trials in Prostate cancer in France (Parenteral) before January 2017
  • 18 Jan 2017 Telix Pharmaceuticals and Atlab Pharma agree to co-develop ATL 201 for Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top